LOS ANGELES (Reuters) - Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates.
The results and an increase in the company's full-year sales outlook sent shares of Gilead, which fell 1.8 percent in regular trading, up 2.6 percent at $103.09 after hours.
14:35 Kim Zolciak Gets 'Cellulite Dimples' Injected With Filler — Watch The NSFW Procedure HERE!14
21:31 Time Warner jumps after hours on report it could sell for $110 per share to AT&T3
12:47 U.S. housing starts tumble on weak multi-family construction activity1
20:10 Intel's quarterly revenue rises 9.1 percent1